NEW YORK (GenomeWeb News) — German biotech company Brain AG and Genencor will collaborate to use metagenomics and metabolic pathway engineering to develop enzymes and biosynthetic pathways for use in developing products that could be used to replace petrochemicals in products such as biofuels, plastics, rubber, adhesives, and cosmetics, Genencor said today.
Genencor, which is a division of Danisco, said it will combine its metabolic engineering and bio-manufacturing with Brain’s metagenomic and screening technologies to produce products. Genencor said Brain’s metagenomic resources include around 150 million genes from “yet uncultured organisms.”
“Brain’s capabilities and expertise in metagenomic enzyme discovery fits nicely within our model for open innovation where we look to make the transition from bench to market more effective and efficient,” Karl Sanford, VP of technology development at Genencor, said in a statement.
This collaboration expands on an earlier one from 2004, in which the two companies worked together to develop a new enzyme product platform.